NCT05931393
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
At risk: Primary completion moved 12 months later.
See at-risk trials from University of Texas Southwestern Medical Center
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Sep 1, 2026 to Sep 1, 2027
- Eligibility criteria expanded, about 37 words
- Study completion pushed from Dec 31, 2028 to Dec 31, 2029
- Secondary endpoints: details revised at 2 of 4 entries
- Notable Primary completion date: Sep 1, 2025 to Sep 1, 2026
- Study completion date: Dec 31, 2027 to Dec 31, 2028
Notable Enrollment target: 36 to 18v6 Show 7 more changesShow less
- Eligibility criteria shortened, about 246 words
- Primary endpoint revised
- Interventions: Cabozantinib 40Mg Tab (Drug), Cabozantinib 80 MG (Drug), Nivolumab (Drug) to Cabozantinib 80 MG (Drug)
- Secondary endpoints revised (4)
- Study arms: 2 to 1
- Study description shortened, about 3 words
- Study title shortened, about 4 words
- Notable Eligibility criteria shortened, about 2 wordsv5
- Notable Eligibility criteria expanded, about 29 wordsv4
Show 2 earlier versionsHide 2 earlier versions
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Dec 1, 2023 to Dec 20, 2023
- Site details revised
- Notable Start date: Sep 1, 2023 to Dec 1, 2023v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Progression free survival of cabozantinib
Timeframe: From time of enrollment/treatment until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason up to 24 months
Secondary (4)
Objective Response Rate of cabozantinib
Disease Control Rate of of cabozantinib
Duration of response of of cabozantinib
Overall survival of of cabozantinib
Arms and interventions
Cabozantinib Dose EscalationExperimental
cabozantinib 80mg PO daily
Drugs: Cabozantinib 80 MG
Sites
1 site in 1 country
- UT Southwestern Medical CenterDallas, Texas, United States